UrApp for Childhood Nephrotic Syndrome Management (Incident Cohort)
Key facts
- Who runs it
- Emory University
- Where
- Atlanta, Minneapolis, and Portland, United StatesSee the 3 sites
- Trial code
- Status
- Completed
- People taking part
- 58 people enrolled
- Started
- 17 Sept 2019
- Ended
- 25 Apr 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Standard of Care
- UrApp
- Record updated
- 6 November 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (7)Hide the full registry criteria
Who can take part
- Caregivers of patients ages 1-17 with steroid sensitive nephrotic syndrome (clinical diagnosis with edema, nephrotic range proteinuria [urine protein to creatinine ratio >2 mg/mg, or ≥ 300 mg/dL or ≥ 3+ protein on urine dipstick], and hypoalbuminemia ≤ 2.5 g/dL; resolution of proteinuria [negative/trace protein on urine dipstick] within 4 weeks of corticosteroid treatment)
- Caregivers of pediatric patients with steroid sensitive nephrotic syndrome diagnosed within 42 days at the time of enrollment
- Access to internet/wireless fidelity (Wi-Fi) in the home
- Caregiver proficiency with the English language
Who cannot take part
- Caregivers of pediatric patients with renal transplantation
- Caregivers of pediatric patients with end-stage kidney disease
- Caregivers of pediatric patients with clinical or histologic evidence of secondary nephrotic syndrome (e.g., systemic lupus erythematosus)
Where in United States
- Children's Healthcare of AltantaAtlanta, United States
- University of Minnesota Children's HospitalMinneapolis, United States
- Oregon Health and Science UniversityPortland, United States
About the trial
What the trial wants to find out
Idiopathic nephrotic syndrome is one of the most common chronic kidney diseases in children. Patients suffer from frequent disease relapses and complications. Self-management is difficult for families and nonadherence is common, with adverse effects on the children's health. UrApp is a mobile application designed to assist families with nephrotic syndrome management. This study will examine whether providing the children's caregivers (or adolescent patients) with UrApp improves self-management and disease outcomes. This study will include 60 caregivers of children with newly diagnosed nephrotic syndrome. Participants will be randomized 1:1 to UrApp or standard of care and followed for 1 year.
The 2 groups in the trial
- UrAppTreatment being tested
Participants randomized to this study arm will use the UrApp mobile application for one year, in addition to receiving the standard of care.
Treatment: Standard of Care and UrApp
- Standard of CareExisting treatment, for comparison
Participants randomized to this study arm will use receive the standard of care for one year.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Pilot Trial of UrApp, a Novel Mobile Application for Childhood Nephrotic Syndrome Management
- Publications
- Record updated
- 6 November 2025